Cns Financial Statements From 2010 to 2024

CNSP Stock  USD 0.12  0.01  7.69%   
Cns Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Cns Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cns Pharmaceuticals financial statements helps investors assess Cns Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cns Pharmaceuticals' valuation are summarized below:
Market Capitalization
5.3 M
Earnings Share
(352.97)
There are currently one hundred twenty fundamental signals for Cns Pharmaceuticals that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate Cns Pharmaceuticals' prevailing fundamental performance against the performance between 2010 and 2024 to make sure the trends are evolving in the right direction.
Check Cns Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cns Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 27 K, Interest Expense of 14.2 K or Selling General Administrative of 3.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Cns financial statements analysis is a perfect complement when working with Cns Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Cns Pharmaceuticals Correlation against competitors.
To learn how to invest in Cns Stock, please use our How to Invest in Cns Pharmaceuticals guide.

Cns Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.6 M1.7 M3.4 M
Slightly volatile
Short and Long Term Debt Total362.4 K300.8 K242.1 K
Slightly volatile
Other Current Liabilities6.1 M5.8 M976.3 K
Slightly volatile
Total Current Liabilities6.4 M6.1 M1.7 M
Slightly volatile
Accounts Payable6.1 M5.8 M1.3 M
Slightly volatile
Cash521.3 K548.7 K2.6 M
Slightly volatile
Cash And Short Term Investments521.3 K548.7 K2.6 M
Slightly volatile
Common Stock Total Equity17.4 K27.4 K15.2 K
Slightly volatile
Common Stock Shares Outstanding71.6 K75.3 K12.2 M
Slightly volatile
Liabilities And Stockholders Equity1.6 M1.7 M3.4 M
Slightly volatile
Capital Surpluse42.1 M40.1 M14.3 M
Slightly volatile
Other Current Assets1.7 MM851.7 K
Slightly volatile
Other Stockholder Equity35.6 M65.1 M17.6 M
Slightly volatile
Total Liabilities6.4 M6.1 M1.7 M
Slightly volatile
Short and Long Term Debt362.4 K300.8 K242.1 K
Slightly volatile
Total Current Assets1.5 M1.6 M3.2 M
Slightly volatile
Short Term Debt362.4 K300.8 K242.1 K
Slightly volatile
Common Stock11.3 K6.2 K12.1 K
Pretty Stable
Other Assets1.091.15185.9 K
Pretty Stable
Deferred Long Term Liabilities279.9 K384.3 K190.5 K
Slightly volatile
Capital Stock11.8 K6.2 K13.5 K
Very volatile
Property Plant And Equipment Net4.7 K4.9 K15.8 K
Slightly volatile
Property Plant And Equipment Gross22.9 K26.9 K20.1 K
Slightly volatile
Property Plant Equipment15.4 K14.5 K17.8 K
Slightly volatile
Good Will267.3 K300.7 K327.5 K
Slightly volatile

Cns Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative3.6 M4.8 M1.8 M
Slightly volatile
Research Development14.8 M14.1 M3.7 M
Slightly volatile
Total Operating Expenses9.9 M18.9 M5.1 M
Slightly volatile
Other Operating Expenses11.4 M18.9 M5.4 M
Slightly volatile
Cost Of Revenue3.9 K4.1 K4.2 K
Slightly volatile
Reconciled Depreciation9.6 K5.6 K4.7 K
Slightly volatile
Selling And Marketing Expenses3.3 K3.7 K4.1 K
Slightly volatile

Cns Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock17.2 M16.4 M5.8 M
Slightly volatile
Depreciation7.2 K4.1 K4.5 K
Slightly volatile
Capital Expenditures3.7 K3.9 K15.8 K
Slightly volatile
Total Cash From Financing ActivitiesM4.6 M4.2 M
Slightly volatile
End Period Cash Flow521.3 K548.7 K2.6 M
Slightly volatile
Change To Netincome1.7 M1.6 M1.1 M
Slightly volatile
Change To Liabilities460.8 K663 K317.4 K
Slightly volatile
Stock Based Compensation1.1 MM517.5 K
Slightly volatile
Begin Period Cash Flow6.8 M10.1 MM
Slightly volatile
Other Non Cash Items473498M
Slightly volatile
Issuance Of Capital Stock9.7 M7.5 M4.4 M
Slightly volatile
Cash And Cash Equivalents Changes5.4 M6.1 M6.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables1.3 M2.5 M996.8 K
Slightly volatile
Capex To Depreciation0.90.94367.1462
Slightly volatile
Payables Turnover7.0E-47.0E-40.006
Slightly volatile
Cash Per Share7.687.31631.1802
Slightly volatile
Days Payables Outstanding540.7 K514.9 K119.8 K
Slightly volatile
Income Quality0.540.75010.5883
Slightly volatile
Current Ratio0.250.25943.0957
Pretty Stable
Graham Number60757879.9045
Slightly volatile
Capex Per Share0.05460.0520.0085
Slightly volatile
Interest Debt Per Share4.214.01070.5617
Slightly volatile
Debt To Assets0.280.17690.4707
Slightly volatile
Days Of Payables Outstanding540.7 K514.9 K119.8 K
Slightly volatile
Ebt Per Ebit0.950.99931.5002
Very volatile
Quick Ratio0.250.25943.0957
Pretty Stable
Net Income Per E B T1.891.191.8296
Slightly volatile
Cash Ratio0.0850.08952.63
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.11.00031.0107
Slightly volatile
Debt Ratio0.280.17690.4707
Slightly volatile

Cns Fundamental Market Drivers

Cash And Short Term Investments548.7 K

Cns Upcoming Events

1st of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Cns Pharmaceuticals Financial Statements

Cns Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Cns Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Cns Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Cns Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-5.2 M-5 M
Cost Of Revenue4.1 K3.9 K

Pair Trading with Cns Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cns Stock

  0.75VALN Valneva SE ADRPairCorr
  0.71VCNX VaccinexPairCorr

Moving against Cns Stock

  0.72BMY Bristol Myers Squibb Sell-off TrendPairCorr
  0.7GILD Gilead SciencesPairCorr
  0.68EWTX Edgewise TherapeuticsPairCorr
  0.6KZR Kezar Life SciencesPairCorr
  0.59VRDN Viridian TherapeuticsPairCorr
The ability to find closely correlated positions to Cns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cns Pharmaceuticals to buy it.
The correlation of Cns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Cns Stock Analysis

When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.